Have you been switched to a biosimilar version of adalimumab?

09 April 2019

Together with NASS, NRAS, and the Psoriasis Association, we want to understand your experiences of switching from Humira to a biosimilar version of adalimumab.

The patent expiry for adalimumab in 2018 saw new medications with similar active properties, known as ‘biosimilars’, become available on the NHS.

This means over recent and coming months, patients treated with Humira may be switched to one of the alternative new biosimilar versions: Amgevita, Hyrimoz, Imraldi, and Hulio.

We want to understand your experiences of this change and to do this we need as many people as possible who have an experience of ‘switching’ to complete our survey.

This short survey will ask questions that will help us to understand how the change was communicated, what kind of information you were given, as well as your experience of the biosimilar product itself. 

The final results will be shared with NHS leaders, healthcare professionals and, of course, you.

To really answer accurately, we’d rather you wait until you’ve been on the biosimilar for 12 weeks (or 6 injections). 

We will keep the survey, kindly hosted by NASS, open for quite a few months so you have plenty of time to get involved.

Take the survey